For help on how to get the results you want, see our search tips.
2 results
Medicine
Referrals Remove Referrals filter
Withdrawn applications Remove Withdrawn applications filter
Orphan designations Remove Orphan designations filter
Medicine type
Exceptional circumstances Remove Exceptional circumstances filter
Biosimilar Remove Biosimilar filter
Accelerated assessment Remove Accelerated assessment filter
Referral PRAC recommendation
Risk minimisation measures Remove Risk minimisation measures filter
Referral decision making model
PRAC-CHMP-EC Remove PRAC-CHMP-EC filter
Categories
Human Remove Human filter
-
List item
Referral: Factor VIII
associated names: Iblias, Elocta, Kovaltry, Nuwiq, Obizur, NovoEight, Voncento, ReFacto AF, Kogenate Bayer, Helixate NexGen, Advate, Article 31 referrals
Status: European Commission final decision, opinion/position date: 14/09/2017, EC decision date: 10/10/2017, Last updated: 05/12/2017 -
List item
Referral: Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free)
daclatasvir, dasabuvir, sofosbuvir, ledipasvir, simeprevir, ombitasvir, paritaprevir, ritonavir, associated names: Sovaldi, Olysio, Viekirax, Harvoni, Exviera, Daklinza, Article 20 procedures
Status: European Commission final decision, opinion/position date: 15/12/2016, EC decision date: 23/02/2017, Last updated: 09/03/2017